Abstract-Islet-activating protein (IAP) is one of the pertussis toxins. The ability of IAP to cause potentiation of insulin secretory responses and promotion of leukocytosis was studied in six animal species (hamsters, rats, guinea pigs, rabbits, dogs and monkeys). The action of IAP on insulin secretion in the animals was estimated by three kinds of tests: effects on epinephrine hyperglycemia, plasma insulin and blood glucose concentrations following the injection of stimuli, and glucose tolerance. Of all animals tested, IAP was most effective in hamsters. Marked hyperinsulinemia was also shown in IAP-treated dogs, rats and monkeys in response to insulin secretagogues, but their sensitivity to IAP was inferior to that of hamsters. In rabbits, IAP was markedly toxic, and the effect on insulin secretion was observed only slightly at a dose close to its minimal lethal dose. In addition, no significant effects of IAP were shown in guinea pigs in the present experi ment. On the other hand, leukocytosis promoting activity of IAP appeared in a dose dependent manner in all animal species; rabbits were the most sensitive to IAP in this regard. It is concluded that both actions of IAP appear differently in different animal species, and the species difference of the effect on insulin secretory responses is in agreement with that on histamine sensitizing activity.
It is well known that the injection of pertussis cells into animals causes diverse physiological and pharmacological changes such as histamine hypersensitivity, promotion of leukocytosis and potentiation of insulin secretory responses (1-3). Islet-activating protein (IAP) is one of the pertussis toxins (4) and has such various biological activities besides its effects on insulin secretion (5). The mechanism by which IAP causes poten tiation of insulin secretory responses has been studied (6-8); the site of action of IAP is adenylate cyclase which is linked to membrane receptors (9). The effect of IAP on insulin secretion has been largely studied in mice (10, 11) and rats (4-8), but it is questionable as to whether or not the effect of IAP appears universally in all animal species because there is a report that the histamine sensitizing activity of pertussis vaccine was shown only in mice and rats, but not in guinea pigs and rabbits (12). These findings urged us to study species differences in the actions of IAP. If diverse actions of IAP would appear differently in animal species, such studies on the species difference would give us clues to elucidate not only the mechanism for these actions but also the mutual relationship between them.
Materials and Methods
Animals used: The following animals were used in the experiments: male golden ham sters (70-80 g), male Wistar rats (120-130 g), male Hartley guinea pigs (400-500 g), male Japanese white rabbits (2.5-3 kg), male and female beagle dogs (9-11 kg), and male and female rhesus monkeys (6-9 kg). Experimental procedures: IAP was in jected i.v. at the doses shown in the Tables and Figs. All animals were fasted for 24 hr before experiments. One day or three days after the injection of IAP, the animals were injected with epinephrine to evaluate the ability of IAP to attenuate epinephrine induced hyperglycemia. The blood glucose concentration was determined by the glucose oxidase method (13) immediately before and at intervals after the epinephrine injection. The percent inhibition of epinephrine hyper glycemia in Table 1 was calculated as (4G,, 4Gt) x 100/4G,,), where 4G, and 4Gt are the increment in blood glucose during a post-epinephrine period in control animals and in IAP-treated animals, respectively. Some animals were used again to examine their insulin secretory responses to some drugs 3 to 7 days after the IAP injection. The plasma insulin concentration was deter mined by the double antibody method (14) using rat or bovine insulin as the standard. From the increase in plasma insulin (JIRI) and glucose (4G) during the first 5 or 15 min after the administration of glucagon or glucose, the insulinogenic index (JIRI/4G) was calculated for each treatment to examine the ability of animals to secrete insulin; it was shown as % of the control.
Intravenous glucose tolerance tests were carried out in four animal species (rats, dogs, guinea pigs and rabbits) 3 days after the injection of IAP. The animals were injected i.v. with a 50% glucose solution at a dose of 1 ml/kg.
The ability of IAP to stimulate leukocytosis was estimated in animals. Total white blood cells were counted in the blood sample 3 days after the injection of IAP by the auto matic blood cell counter (CC-120, Toa Denshi).
Blood samples were taken from the heart in hamsters, the tail vein in rats, the ear vein in guinea pigs and rabbits, and the femoral vein in dogs and monkeys. All experiments were carried out without anesthesia.
Drugs used: IAP was purified from the 48 hr culture supernatant fluids of Bordetella pertussis as described elsewhere (4). 1251 insulin and anti-insulin guinea pig serum for radioimmunoassay were purchased from Dainabot. Glucagon was from the Sigma Chemical Co. and epinephrine bitartrate from the Nakarai Chemical Co. Blood glucose concentrations were determined by the New Glucostat kit from Worthington Co.
Statistics: The statistical analysis of differ ences between mean values were carried out using the Student's t-test.
Results
Effect of IAP treatment on epinephrine hyperglycemia: Treatment of mice and rats with IAP resulted in marked attenuation of epinephrine-induced hyperglycemia (5, 10). The attenuation of epinephrine hyperglycemia in these animals resulted from the hypo glycemic action of insulin secreted in response to epinephrine challenge (5). Hence, the epinephrine test seemed to be a brief and useful means to estimate the action of IAP in vivo. Table 1 shows the effect of IAP treatment on epinephrine hyperglycemia in six animal species. Marked attenuation of epinephrine hyperglycemia was reproduced in a dose dependent manner in IAP-treated rats. IAP pretreatment was also effective in inhibiting epinephrine hyperglycemia in the hamsters; the dose required for the attenuation was much lower in hamsters than rats. In hamsters, IAP significantly attenuated epin ephrine hyperglycemia at a dose as low as 0.02 ,ug/kg, and IAP completely inhibited it at 0.1 fig/kg. The ability of IAP to attenuate IAP was injected i.v. one day before in hamsters, rats and dogs or 3 days before in guinea pigs, rabbits and monkeys. In experiment A, blood samples were taken immediately before and 1 hr after the injection of epinephrine.
All the values of blood glucose are shown as percent of the pre-epinephrine value. The fasting blood glucose concentration was significantly influenced only in hamsters by IAP, and the concentrations in this experiment were similar to those 3 days after (Table 2 ). *P<0.05, **P<0.01 significant difference from the nontreated group. epinephrine hyperglycemia was demonstrated in dogs as well. Epinephrine induced almost equal hyperglycemia immediately after the injection in IAP-treated and nontreated dogs, but it was followed by hypoglycemia 30 min later in the IAP-treated group. On the contrary, no attenuation of epinephrine hyperglycemia was shown in IAP-treated guinea pigs, rabbits and monkeys. The epinephrine test was carried out 3 days after the IAP injection in these animals because IAP activity has been shown to become most effective 3 to 10 days after the treatment (5). In addition, the highest doses of IAP used in the rabbits and the guinea pigs were almost close to its minimal lethal doses, which were estimated to be 15-30 ug/kg in guinea pigs and 2 ug/kg in rabbits. In the case of monkeys, the dose used was thirty-fold less than the lethal dose. In any case, hamsters, dogs and Hamsters, rats and dogs were injected i.v. with IAP 3 days before, and monkeys were injected with IAP 7 days before the experiments. The time of the determination of concentrations of glucose and insulin is a) 5 min, b) 15 min or c) 30 min after the injection. The insulinogenic indices were calculated from the peak concentration of insulin after stimulation and the concentration of glucose at the time as described in Materials and Methods. The indices show 15-min values after glucose load in hamsters and rats and 5-min values after glucagon challenge in dogs and monkeys. The glucose concentrations 5 min after glucagon were 187±3 (control), 19215 (0.1 pg/kg), and 183±7 (1 ,ug/kg) in the dogs and 98 (control) and 104 (1 ug/kg) in the monkeys. Since epinephrine decreased the insulin concentration of control groups, the indices were not calculated. *P<0.05, *P<0.01 : significant difference from the nontreated group. rats were susceptible to the action of IAP to attenuate epinephrine hyperglycemia, where as guinea pigs, rabbits and monkeys were much less sensitive.
The effect of IAP treatment on insulin secretory responses: In Table 2 , the ability of IAP to potentiate insulin secretory re sponses was examined. The rats treated with even the lowest dose of IAP exhibited more hyperinsulinemia in response to glucose than did nontreated rats despite their normal susceptibility to epinephrine at this dose (see Table 1 ). The increment of blood glucose following glucose injection was clearly at tenuated in the rats treated with higher doses (over 2 /lg/kg) of IAP, although their plasma insulin concentrations were variable. As a result, the insulinogenic indices increased in proportion to the amount of IAP injected. The IAP-treated hamsters responded to glucose challenge similarly to rats, and the increase in blood glucose was significantly suppressed by 0.1 ug/kg of IAP; however, their fasting concentrations of blood glucose and plasma insulin were markedly influenced by the doses of IAP. IAP treatment resulted in more hypoglycemia and hyperinsulinemia in a dose-dependent manner. Such an effect of IAP as found in hamsters was not shown in other animals.
The dogs treated with IAP showed a dose-dependent potentiation of insulin secretory responses to stimuli. After treatment with 0.1 ug/kg, they showed more hyper insulinemia in response to epinephrine or glucagon than the nontreated dogs, but such hyperinsulinemia was not associated with hypoglycemia. On the other hand, the dogs treated with 1 /ig/kg of IAP showed marked hyperinsulinemia followed by hypo glycemia at 30 min. In the monkeys, IAP was effective in potentiating their insulin secretory responses to epinephrine and glucagon, but there was no difference in blood glucose concentrations between IAP-treated and non treated groups. Thus, more IAP would be required to influence the blood glucose concentration in monkeys. When tolbutamide was injected into guinea pigs, there was no difference in its hypoglycemic action between IAP-treated and nontreated groups (data not shown).
Effect of IAP treatment on glucose tolerance pattern: Fasted animals treated with either saline or IAP 3 days before were injected with a 50% glucose solution, and changes in blood glucose concentrations were determined (Fig. 1) . The rate of disappearance of glucose (k-value) was calculated ac cording to the formula of Conard (15) from the regression coefficient of the semilogari thmic plot of blood glucose versus time between 5 and 30 or 60 min after glucose injection. These values are shown in Table 3 together with the increment of plasma insulin during glucose tolerance tests. It is shown that the disappearance of injected glucose from the circulation was accelerated in dogs and rats by the IAP treatment, but not in guinea pigs and rabbits. The increase of plasma insulin following glucose injection were more marked in IAP-treated groups than nontreated groups. IAP (1 ,ag/kg) The k-value was calculated from the regression coefficient of a semilogarithmic plot of blood glucose concentration against values between 5 and 30 or 60 min after glucose load based on the data in Fig. 1 . 4 Insulin shows the difference between the peak value (almost 5 min) and the value immediately before a glucose load. N.D.: not determined. Fig. 2 . Effect of IAP in promoting leukocytosis. Blood samples from animals which had been injected i.v. with IAP 3 days before were counted for the number of total white blood cells. 0 rats, • rabbits, A dogs, V hamsters, / guinea pigs. Each point shown is the percent of the number of white blood cells in nontreated animals. Number of observations is 3 to 4. *P<0.05, **P<0.01 : significant difference from the nontreated group. treated rabbits showed more hyperinsulinemia than nontreated rabbits, but with treatment at lower doses of IAP, the rabbits did not show any significant increase in the plasma level of insulin as compared to nontreated animals (data not shown).
Effect of IAP treatment to cause Ieukocy tosis: IAP has been shown to promote leukocytosis besides its histamine sensitizing and insulin secretory activities in mice (5). We measured the number of total white blood cells in several animal species which had been injected with IAP 3 days before (Fig. 2) . IAP increased the number of these cells in all animal species, but the most striking effect of IAP was observed in the rabbits. The guinea pigs also responded to IAP, and marked leukocytosis was observed at doses more than 1 ucg/kg of IAP. The hamsters and the dogs showed only a weak leukocytosis even at the IAP doses which caused marked potentiation of insulin secretory responses. Thus, the species differ ence in the leukocytosis promoting activity of IAP differed from the species difference for its insulin secretory activity.
Discussion
The ability of IAP to potentiate insulin secretory responses in animals were ex amined by comparing changes in blood concentrations of insulin and glucose in response to epinephrine, glucose and other drugs between IAP-treated and nontreated animals. It has been already shown that insulin secretion following the injection of glucose is not always proportional to the amount of IAP injected before because fur ther secretion of insulin is attenuated as a result of the hypoglycemic action of insulin previously secreted (4). Therefore, the change in blood glucose concentration is an impor tant factor to evaluate the effect of IAP, and the insulinogenic index would reflect the ability of animals to secrete insulin.
Hamsters were the most sensitive to IAP of all the animal species tested. There was a complete inhibition of epinephrine hyper glycemia, and marked potentiation of insulin secretion was associated with suppressed increment of blood glucose following glucose challenge at a dose of IAP as low as 0.1 lag/ kg. Dogs would be more sensitive to IAP than rats, but their sensitivity was inferior to that of hamsters. The dogs treated with 1 itg/ kg of IAP showed marked hyperinsulinemia in response to epinephrine or glucagon, followed by hypoglycemia, and also ac celerated disappearance of injected glucose. With 1 ug/kg of IAP, the rats showed about 40% inhibition of epinephrine hyperglycemia and more hyperinsulinemia to glucose chal lenge than nontreated rats, but much a higher dose (10 ug/kg) was needed to accelerate disappearance of injected glucose. As monkeys showed potentiation of insulin secretory responses to some hormonal stimuli at a dose of 1 ag/kg, which was far less than its minimal lethal dose, they would be more sensitive to IAP than rabbits and guinea pigs. The sensitivity of monkeys might be almost equal to that of rats. However, the reason why IAP treatment did not influence the blood glucose concentration despite a high insulinogenic index remained unclarified. In this regard guinea pigs and rabbits were almost insensitive to the action of IAP. The rabbits could respond to IAP at such a high dose as close to its minimal lethal dose and showed only a slight potentiation of insulin secretion after glucose challenge. There was no significant effect of IAP on carbohydrate metabolism in guinea pigs. Consequently, the sensitivity of animals to the effect of IAP on insulin secretion would be in the order: hamster>dogs>rats>monkeys> rabbits, guinea pigs.
The species difference in the action of IAP would be in agreement with that in histamine sensitizing activity of pertussis vaccine (12). Such a similar species difference in both actions might support our previous idea that histamine hypersensitivity is partly accounted for by the hyperinsulinemic action of IAP (16). It was shown that far less histamine was lethal due to severe hypo glycemia in IAP-treated rats compared to the nontreated rats. The hypoglycemia resulted from the hypoglycemic action of insulin secreted via the 8-adrenergic action of epinephrine released from the adrenal medullae in response to the injection of histamine (16). It is likely, therefore, that the lack of pertussis vaccine-induced histamine hypersensitivity in guinea pigs and rabbits might be partly explained by the inability of IAP to potentiate insulin secretory responses in these animal species.
The reason for the ineffectiveness of IAP in rabbits and guinea pigs has not been elucidated as yet, but there are noteworthy findings with regard to the high sensitivity of hamsters and dogs to IAP. Cegrell (17) and Levovitz and Feldman (18) have demon strated that the number of adrenergic nerve fibers innervating the islet B cell is very different in different animal species, and the order is hamsters>dogs>other animals. This order would be somewhat consistent with that of the potency of IAP on the islet B cell and might suggest a more important role for a-adrenergic control in suppressing insulin secretion in hamsters and dogs than other animal species. Thus it is likely that IAP could cause a more dramatic effect on insulin secretion in islets of hamsters and dogs which are highly innervated by adrenergic nerves than those of other animals less innervated, taking into con sideration the fact that the most characteristic effect of IAP in the B cell is reversal of a adrenergic receptor mediated inhibition of insulin secretory responses (6-9).
The species difference concerning the leukocytosis promoting activity of IAP, which was clearly different from the species differ ence in the effect of IAP on pancreatic islets. IAP was most effective in promoting leukocytosis in rabbits, and other animal species including guinea pigs equally re sponded to IAP; however, the sensitivity of other animals was much inferior to that of the rabbits. IAP was markedly toxic in rabbits and the minimal lethal dose was about 2-3 i g/kg, which was far lower than those in other animals (unpublished data). The high toxicity of IAP in rabbits has not been explained as yet, but it seems to be important to elucidate the relationship between the extraordinary leukocytosis and the cause of death.
Promotion of leukocytosis by the pertussis toxins is thought to be due to the inability of leukocytes to return to lymphoids, but not due to proliferation of new cells (19, 20) . However, it is not known what cells or tissues are responsible for the promotion of leukocytosis. On the other hand, when IAP evokes various changes in functions of cells, it would first bind to the receptors specific for IAP on the cell surface. Although the receptors have not been identified, it is likely that number or affinity of the receptors is largely different among animal species and cell types. As one of the factors involved in the different sensitivity of IAP between leukocytosis and insulin secretion in rabbits, one might think that the affinity of receptors to IAP is much higher in the cells responsible for promotion of leukocytosis than the islet B cell. Consequently, injected IAP may bind preferentially to the former cells during circulation, thereby causing marked leukocy tosis rather than potentiation of insulin secretory responses. In any case, it would be important to find the cells or the tissues responsible for promotion of leukocytosis and clarify the mechanism underlying the action. Such a study would give us a clue to solve the very reverse species difference in both actions of IAP.
